No Data
CellSeed: Confirmation
CellSeed: Financial Report - 24th Term (2024/01/01 - 2024/12/31)
Aftermarket [Stocks that moved and stocks that were traded]
*Grimmus <3150> 2417 +109 changed its dividend policy and upwardly revised the Financial Estimates for dividends for the fiscal year ending March 2025. * Tsubakimoto Industrial <6309> 4265 +1451 will split its stock by 3 shares. An upward revision of the dividends and a relaxation of the conditions for shareholder benefits were also announced. * Toho <9602> 7419 +141 has revised its dividend forecast upward for the fiscal year ending February 2025. The upside remains heavy. * Book Off Group Holdings <9278> 1492 +43 announced a Share Buyback of up to 12.14% of the issued shares and a purchase委託. Today is the 11th.
Stocks with a limit-up or limit-down in the afternoon session.
■Limit up <1787> Nakabo Tech <3985> Temona <4882> Perseus Proteomics <4896> Kei Pharma <7681> Leoclan <7776> Cellseed ■Limit down *Includes temporary limit up and down (indicative prices).
The market is stable, supported by the rise in U.S. stocks, but resistance may be strong at higher levels.
[Emerging Markets Individual Stock Strategy] Today's Emerging Markets are expected to show a solid performance. On the US Stock Market yesterday, October 24, the Dow Inc rose significantly by 597.97 points (+1.42%) to 42,583.32 dollars. Reports suggested that the Trump administration's 'reciprocal tariffs' would be focused, and the unexpected rise in the March Services PMI supported stock prices. The buybacks in the high-tech sector continued, expanding the gain into the latter part of the day. Today's Emerging Markets are likely to experience a favorable buying trend.
Mirai Works, Cell Seed and others.
The acquisition of shares in Sky 365, which is involved in MSP (operations, monitoring, maintenance) business and Software Development related to Beex Cloud. <4594> Brightpath has revised its Financial Estimates, projecting an operating loss of 1.114 billion yen for this term, compared to 0.925 billion yen previously. <4598> A clinical phase 2/3 comparative trial of DELTA-PDFP-17729 has begun. <4881> A large exercise of the 12th subscription rights of Fanpepp with price adjustment clauses will start on the 17th, with the number of shares to be delivered being 85.